| Literature DB >> 31011523 |
Huayi Qu1, Dasen Li1, Shun Tang1, Jie Zang1, Yifei Wang1, Wei Guo1.
Abstract
BACKGROUND: Functional reconstruction following resection of pelvic tumours with the ileum and the acetabulum involvement is challenging and demanding. The aim of this study was to evaluate the results of these patients receiving pelvic reconstruction with a femoral head autograft plus a hemipelvic prosthesis.Entities:
Keywords: Autograft; Limb salvage surgery; Orthopaedic oncology; Pelvic tumour; Prosthesis
Year: 2019 PMID: 31011523 PMCID: PMC6460299 DOI: 10.1016/j.jbo.2019.100234
Source DB: PubMed Journal: J Bone Oncol ISSN: 2212-1366 Impact factor: 4.072
Fig. 1a, A modular pelvic prosthesis was used to reconstruct defects after type II resections of pelvic tumours. The prosthetic set consists of iliac components with variable length bushing, a metal acetabular component, a polyethylene acetabular component, and a femoral component. b, A anteroposterior view of a typical pelvic prosthesis after a type II +III resection. The residual ilium served as a pedestal for the prosthesis to be implanted. c, A anteroposterior view of a femoral head autograft and pelvic prosthesis for a type I+II tumor resection. The femoral head autograft fixed to the lateral side of sacrum serves as a pedestal for the prosthesis.
Fig. 2A 13-year-old female patient had an osteosarcoma at her right pelvis. The tumour involved the ilium and the roof of the acetabulum. a, A anteroposterior view after the chemotherapy. b, following the tumour resection, the femoral head was fixed to the lateral side of the sacrum, then a pelvic prosthesis was fixed to the femoral head and the sacrum and the femoral component was implanted. c, The specimen of the resected tumour. d, The autograft was healed 9 months after the surgery on a CT scan.
General data, complications, and follow-up data of all patients.
| No. | Age | Gender | Tumour | Location | Patient's status | Bone healing (months) | Relapse | Follow-up (months) | Complications | MSTS-93 score |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 31 | F | CS | I+II+III | NED | 9 | 119 | 17 | ||
| 2 | 36 | F | CS | I+II | NED | 12 | 110 | Deep infection | 11 | |
| 3 | 36 | F | CS | I+II+III | DOD | Local, lung | 20 | Dislocation | ||
| 4 | 18 | F | OS | I+II+III | NED | 9 | 103 | WD | 20 | |
| 5 | 35 | F | OS | I+II | DOD | 9 | Lung | 23 | Dislocation | 21 |
| 6 | 70 | M | RCC | I+II | NED | 12 | 86 | DVT | ||
| 7 | 58 | F | OS | I+II+III | NED | 9 | 82 | 25 | ||
| 8 | 16 | M | OS | I+II+III | DOD | 6 | Local | 28 | 16 | |
| 9 | 51 | M | CS | I+II | DOD | 12 | Lung | 28 | 16 | |
| 10 | 53 | M | UPS | I+II | DOD | 9 | Lung | 29 | 18 | |
| 11 | 48 | M | OS | I+II | DOD | Lung | 9 | Deep infection | 16 | |
| 12 | 53 | F | CS | I+II | NED | 9 | Local | 57 | 17 | |
| 13 | 13 | M | OS | I+II+III | NED | 12 | 50 | 18 | ||
| 14 | 39 | F | CS | I+II+III | DOD | Local, lung | 14 | |||
| 15 | 59 | F | LOS | I+II+III | NED | 9 | 39 | 26 | ||
| 16 | 30 | M | OS | I+II | AWD | 9 | Lung, bone | 39 | 21 | |
| 17 | 62 | M | CS | I+II | AWD | 9 | Local | 38 | Deep infection | |
| 18 | 18 | M | EWS | I+II+III | NED | 9 | 36 | 13 | ||
| 19 | 15 | F | EWS | I+II | NED | 12 | 47 | 16 | ||
| 20 | 15 | M | OS | I+II+III | DOD | 15 | Lung | 30 | 15 | |
| 21 | 23 | M | OS | I+II | NED | 12 | 27 | 14 | ||
| 22 | 25 | M | CS | I+II | NED | 6 | 24 | 26 |
F, female. M, male. CS, chondrosarcoma. OS, osteosarcoma. RCC, renal clear cell carcinoma. EWS, Ewing's sarcoma. UPS, undifferentiated pleomorphic sarcoma. LOS, low grade osteosarcoma. NED, no evidence of disease; DOD, dead of disease; AWD, alive with disease. WD, wound dehiscence. DVT, deep vein thrombosis.
These patients were excluded because of local recurrence.
Oncological results, functional status, and complication analysis.
| Reference | Case numbers | Follow-up months (range) | Reconstruction | Death perioperatively | Local recurrence | Five-year survival | Deep infection | Dislocation | Revision | Wound dehiscence | MSTS-93 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gebert (2011) | 62 | 30 (5–185) | HT | 0 | 6 (9.6%) | 80.5% | 20 (32.2%) | 6 (9.6%) | 25 (40.3%) | 14 (22.5%) | 62% |
| Campanacci D | 17 | 34.6(2–137) | ALP | 0 | 3(17.6%) | NA | 6(35.3%) | 1(5.9%) | NA | NA | 53.3% |
| Wafa | 11 | 51.6(4–185) | IAP | 0 | 0 | NA | 3(27.2%) | 1(9.1%) | 2(18.2%) | 1(9.1%) | 74.2% |
| Bo (2015) | 50 | 54 (12–113) | MP | 0 | 18% | 64% | 14% | 4% | 10% | 28% | 61.4% |
| Zang (2014) | 17 | 33 (15–59) | RSP | 0 | 6 (35%) | 62.4% | 2 (11.7%) | 1 (5.8%) | 0 | 5 (29.4%) | 58% |
| Gordon (2005) | 21 | 5–180 | ALP | 2 | 3 (15%) | 40% (NED) | 9 (47.3%) | 0 | 3 (30%) | NA | 64% |
| This study | 22 | 47 (9–119) | AUP | 0 | 5 (22.7%) | 61.7% | 3 (13.6%) | 2 (9%) | 0 | 1 (4.5%) | 60.7% |
HT, hip transposition. MP, modular prosthesis. RSP, rod and screw + prosthesis. ALP, allograft prosthesis. AUP, autograft prosthesis. IAP, irradiated autograft and prosthesis. + Survival rate at the last follow-up. NA, not available.
The total number of the case series was 33 patients with 17 patients received a type I/II or I/II/III resection.
The total number of the case series was 18 patients with 11 patients received a type I/II resection.
Thirty-eight patients received type I/II or I/II/III resections.
The authors reported two groups of patients. One group of the patients included twenty-one patients who received type I/II or I/II/III resections.